BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Real-time Borsa Italiana 16:39:42 18/06/2024 BST | ||
| 2.385 EUR | -2.45% |
|
| Current month | +10.38% | ||
| 1 month | +16.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 18/06/24 | 2.385 | -2.45% |
| 17/06/24 | 2.445 | -5.23% |
| 14/06/24 | 2.58 | +7.95% |
| 13/06/24 | 2.39 | -2.65% |
| 12/06/24 | 2.455 | +2.29% |
Real-time Borsa Italiana
Last update June 18, 2024 at 04:39 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| S35524 | |
| ISIN | DE000SW9K4F0 |
| Date issued | 30/04/2024 |
| Strike | 10,447 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.74 € |
|---|---|
| Lowest since issue | 1.82 € |
| Spread | 0.01 € |
| Spread % | 0.42% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.7
USD
Average target price
174.4
USD
Spread / Average Target
+10.62%
- Stock Market
- Certificates
- S35524 Certificat